Blueprint Medicines Corp’s recent filing unveils that its Director Albers Jeffrey W. unloaded Company’s shares for reported $1.35 million on Dec 19 ’24. In the deal valued at $89.77 per share,15,000 shares were sold. As a result of this transaction, Albers Jeffrey W. now holds 157,557 shares worth roughly $13.92 million.
Then, Rossi Christina sold 2,274 shares, generating $218,098 in total proceeds. Upon selling the shares at $95.91, the CHIEF OPERATING OFFICER now owns 69,383 shares.
Before that, Albers Jeffrey W. bought 15,000 shares. Blueprint Medicines Corp shares valued at $1,346,633 were divested by the Director at a price of $89.78 per share.
JP Morgan initiated its Blueprint Medicines Corp [BPMC] rating to an Overweight in a research note published on November 14, 2024; the price target was $126. A number of analysts have revised their coverage, including UBS’s analysts, who began to cover the stock in late October with a ‘”a Neutral”‘ rating. Stephens began covering BPMC with “an Overweight” recommendation on May 14, 2024. Leerink Partners revised its rating on May 06, 2024. It rated BPMC as “a Market perform” which previously was an “an Underperform”.
Price Performance Review of BPMC
On Friday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock jump 1.32% to $88.35. Over the last five days, the stock has lost -3.57%. Blueprint Medicines Corp shares have risen nearly 1.30% since the year began. Nevertheless, the stocks have fallen -0.44% over the past one year. While a 52-week high of $121.90 was reached on 01/02/25, a 52-week low of $72.24 was recorded on 01/03/25. SMA at 50 days reached $92.58, while 200 days put it at $96.67.
Levels Of Support And Resistance For BPMC Stock
The 24-hour chart illustrates a support level at 86.99, which if violated will result in even more drops to 85.62. On the upside, there is a resistance level at 89.49. A further resistance level may holdings at 90.62. The Relative Strength Index (RSI) on the 14-day chart is 41.43, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.93, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 80.48%. Stochastics %K at 13.44% indicates the stock is a buying.
How much short interest is there in Blueprint Medicines Corp?
A steep rise in short interest was recorded in Blueprint Medicines Corp stocks on 2024-12-13, growing by 0.62 million shares to a total of 4.53 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 3.91 million shares. There was a rise of 13.6%, which implies that there is a positive sentiment for the stock.
